1. Wu CJ*, Lee PC, Hung YW, Lee CJ, Chi CT, Lee IC, Hou MC, Huang YH. Lenvatinib plus pembrolizumab for systemic therapy-naïve and -experienced unresectable hepatocellular carcinoma. Cancer Immunol Immunother. 2022 Mar 28. doi: 10.1007/s00262-022-03185-6. Epub ahead of print. PMID: 35347395.

2. Wu CJ*, Chau GY, Lee IC, Huo TI, Su CW, Hou MC, Huang YH. Early and late recurrence of surgically resected hepatitis B virus-related hepatocellular carcinoma on nucleos(t)ide analogues therapy. J Formos Med Assoc. 2021 Aug;120(8):1563-1571. doi: 10.1016/j.jfma.2020.11.019. Epub 2020 Dec 15. PMID: 33334659.

3. Lee PC, Wu CJ*, Hung YW, Lee CJ, Chi CT, Lee IC, Yu-Lun K, Chou SH, Luo JC, Hou MC, Huang YH. Gut microbiota and metabolites associate with outcomes of immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma. J Immunother Cancer. 2022 Jun;10(6):e004779. doi: 10.1136/jitc-2022-004779. PMID: 35738801; PMCID: PMC9226985. (co-first author)

4. Lee IC, Chao Y, Lee PC, Chen SC, Chi CT, Wu CJ*, Wu KC, Hou MC, Huang YH. Determinants of Survival and Post-Progression Outcomes by Sorafenib-Regorafenib Sequencing for Unresectable Hepatocellular Carcinoma. Cancers (Basel). 2022 Apr 15;14(8):2014. doi: 10.3390/cancers14082014. PMID: 35454919; PMCID: PMC9030368.

5. Lee IC, Lei HJ, Chau GY, Yeh YC, Wu CJ*, Su CW, Huo TI, Chao Y, Lin HC, Hou MC, Huang YH. Predictors of long-term recurrence and survival after resection of HBV-related hepatocellular carcinoma: the role of HBsAg. Am J Cancer Res. 2021 Jul 15;11(7):3711-3725. PMID: 34354870; PMCID: PMC8332858.

6. Liu YC, Wu CJ*, Ko PS, Chien SH, Fan NW, Wang HY, Gau JP, Liu CJ, Hsiao LT, Chiou TJ, Liu CY, Liu JH. Mycobacterial infections in adult recipients of allogeneic hematopoietic stem cell transplantation: A cohort study in a high endemic area. J Microbiol Immunol Infect. 2020 Apr;53(2):274-282. doi: 10.1016/j.jmii.2018.07.001. Epub 2018 Jul 26. PMID: 30082145.